Bayer HealthCare (BYR.L,BAYRY.PK,BAYZF.PK) said it has submitted an application for marketing authorization in the European Union for a new transparent low dose contraceptive patch. France would serve as the reference member state in the decentralized procedure for gaining marketing authorization in countries in the European Union.
"Once approved and launched, our contraceptive patch will provide an additional choice among contraceptive methods especially for women who are looking for an aesthetic, convenient weekly transdermal application with a low hormonal dose," according to Flemming Ornskov, Chief Marketing Officer - Strategic Marketing General Medicine at Bayer HealthCare Pharmaceuticals.
The data from clinical trials, including 4,200 women globally, demonstrate that the new low dose contraceptive patch is an efficacious contraceptive with a good safety profile. The contraceptive patch is small, round and transparent and contains 0.55 mg ethinylestradiol and 2.1 mg gestodene.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.